Expression of the Y-Encoded TSPY is Associated with Progression of Prostate CancerReportar como inadecuado




Expression of the Y-Encoded TSPY is Associated with Progression of Prostate Cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

1

Division of Cell and Developmental Genetics, Department of Medicine, VA Medical Center, University of California, San Francisco, CA 94121, USA

2

Department of Urology, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan





*

Author to whom correspondence should be addressed.



Abstract TSPY is a Y-encoded gene that is expressed in normal testicular germ cells and various cancer types including germ cell tumor, melanoma, hepatocellular carcinoma, and prostate cancer. Currently, the correlation between TSPY expression and oncogenic development has not been established, particularly in somatic cancers. To establish such correlation, we analyzed the expression of TSPY, in reference to its interactive oncoprotein, EEF1A, tumor biomarker, AMACR, and normal basal cell biomarker, p63, in 41 cases of clinical prostate cancers CPCa, 17 cases of latent prostate cancers LPCa, and 19 cases of non-cancerous prostate control by immunohistochemistry. Our results show that TSPY was detected more frequently 78% in the clinical prostate cancer specimens than those of latent prostate cancer 47% and control 50%. In the latent cancer group, the levels of TSPY expression could be correlated with increasing Gleason grades. TSPY expression was detected in seven out of nine high-grade latent cancer samples Gleason 7 and more. The expression of the TSPY binding partner EEF1A was detectable in all prostate specimens, but the levels were higher in cancer cells in clinical and latent prostate cancer specimens than normal prostatic cells. These observations suggest that expressions of TSPY and its binding partner EEF1A are associated with the development and progression of prostate cancer. View Full-Text

Keywords: prostate cancer; TSPY; EEF1A; latent cancer; clinical cancer prostate cancer; TSPY; EEF1A; latent cancer; clinical cancer





Autor: Tatsuo Kido 1, Shingo Hatakeyama 2, Chikara Ohyama 2 and Yun-Fai Chris Lau 1,*

Fuente: http://mdpi.com/



DESCARGAR PDF




Documentos relacionados